Tang Capital Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Tang Capital Management’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-200,000	Closed	-$3.08M	–	173
2025 Q3	$3.08M	Hold	200,000	–	–	0.12%	109
2025 Q2	$1.87M	Hold	200,000	–	–	0.09%	121
2025 Q1	$2.46M	Buy	200,000 +100,000	+100%	+$1.41M	0.14%	104
2024 Q4	$1.32M	Buy	+100,000	New	+$1.71M	0.09%	123

Other funds holding SNDX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Tang Capital Management's SNDX Position: Q4 2025 in Review

Tang Capital Management sold out of Syndax Pharmaceuticals (SNDX) in Q4 2025, closing a stake of 200,000 shares — an estimated $3.08M sold.

Tang Capital Management first reported a position in SNDX in Q4 2024 and held it in 4 quarters. The position peaked at $3.08M in Q3 2025. 229 funds tracked by Wall St. Rank hold SNDX as of Q4 2025.

Tang Capital Management reported no remaining Syndax Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Tang Capital Management sold 200,000 Syndax Pharmaceuticals shares in Q4 2025, an estimated $3.08M.
Tang Capital Management first reported a position in Syndax Pharmaceuticals in Q4 2024 and held it in 4 quarters.
Tang Capital Management's Syndax Pharmaceuticals position peaked at $3.08M in Q3 2025.
229 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q4 2025.

Based on Tang Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.